New drug aims to stop aggressive nose cancer from coming back
NCT ID NCT07303283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the drug becotatug vedotin can prevent cancer from returning in 140 patients with high-risk nasopharyngeal carcinoma who have completed standard chemo-radiation. Participants are randomly assigned to receive the drug or standard care. The main goal is to see if the drug extends the time without cancer recurrence or death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could avoiding Pre-Radiation tooth removal protect jaw health?
- Can a blood test and MRI tailor cancer therapy to each patient?
- Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
- Can an immune booster after lung cancer surgery keep the disease at bay?